Ranking Profile - Histogen Inc

Introduction

Histogen Inc (Histogen), formerly Conatus Pharmaceuticals Inc is a biotechnology company that develops and commercializes novel medicines for the treatment of liver diseases. The company’s lead pipeline candidate includes emricasan, an orally active pan-caspase protease inhibitor which is designed to reduce the activity of human caspases and is intended for the treatment of various indications such as post-orthotopic liver transplant, nonalcoholic steatohepatitis (NASH) cirrhosis, and NASH fibrosis. Its other preclinical product candidates include IDN-7314, a pan-caspase inhibitor intended for the treatment of primary sclerosing cholangitis. Histogen is headquartered in San Diego, California, the US.

Company info

Country (HQ): United States
Sector: Pharmaceuticals and Healthcare
Market Cap (US$ m): 3
Revenue (US$ m): 4 (2022)

Innovation ranking

284

Innovation score

Closest peers in the Pharmaceuticals and Healthcare sector

Innovation Ranking

Company
Headquarters
Sector

Johnson & Johnson

United States

Pharmaceuticals and Healthcare

F. Hoffmann-La Roche Ltd

Switzerland

Pharmaceuticals and Healthcare

Histogen Inc

United States

Pharmaceuticals and Healthcare

EyeGate Pharmaceuticals Inc

United States

Pharmaceuticals and Healthcare

Shin Poong Pharm Co Ltd

South Korea

Pharmaceuticals and Healthcare

Are you ranked? Get the Innovation Ranking Report

  • Company Ranking Report
    • If your company is ranked you can get more detailed information about your ranking through the Innovation Ranking Report
    • Full company scorecard across the 3 pillars and 19 data indicators that make up the ranking score
    • Contextualised information on the company's standing in relation to peers
    • Key takeaways on the company's position in its sector, country and its standing in relation to key industry themes
    • Tips on how to use your ranking to tell a unique and compelling story in your marketing, benchmarking and hiring processes
  • Rosettes
  • Certificate of Achievement
  • Press release
Screenshot of Deal Makers